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Background: Strokepatientswithdiabeteshave ahighermortality rate,worseneurologicoutcome, andmore severedisability
than those without diabetes. Results from clinical trials comparing the outcomes of stroke seen with intensive glycemic
control in diabetic individuals are conﬂicting. Therefore, the present study was aimed to identify the key factor involved in
the neuroprotective action of insulin beyond its hypoglycemic effects in streptozotocin-diabetic rats with ischemic stroke.
Methods: Long-Evans male rats were divided into three groups (control, diabetes, and diabetes treated with insulin) and
subjected to focal cerebral ischemia-reperfusion (FC I/R) injury.
Results: Hyperglycemia aggravated FC I/R injuries with an increase in cerebral infarction and neurologic deﬁcits, inhi-
bition of glucose uptake and membrane-trafﬁcking activity of glucose transporter 1, and reduction of Akt and endothelial
nitric oxide synthase (eNOS) phosphorylation in the cerebrum. Insulin treatment alleviated hyperglycemia and the
symptoms of diabetes in streptozotocin-diabetic rats. Insulin administration also signiﬁcantly decreased cerebral infarc-
tion and neurologic deﬁcits and increased phosphorylation of Akt and eNOS protein in the cerebrum of FC I/R-
injured diabetic rats. However, the glucose uptake and membrane trafﬁcking activity of glucose transporter 1 in the
cerebrum were not restored by insulin treatment. Coadministration of the eNOS inhibitor, N-iminoethyl-L-ornithine,
with insulin abrogated beneﬁcial effects of insulin on cerebral infarct volume and neurologic deﬁcits in FC I/R-injured
diabetic rats without affecting the hypoglycemic action of insulin.
Conclusions: These results suggest that eNOS activation is required for the neuroprotection of insulin against ischemic
stroke in patients with diabetes. (J Vasc Surg 2014;59:483-91.)
Clinical Relevance: Our ﬁndings indicate that the impact of insulin in patients with diabetes with acute ischemic stroke is
concurrently dependent on both endothelial nitric oxide synthase (eNOS) signaling and antihyperglycemic effects. When
eNOS dysfunction (eg, vascular endothelial dysfunction) is developed in patients with diabetes, the beneﬁcial effect of insulin
might be diminished in acute ischemic stroke in spite of its preserved antihyperglycemic effect. For diabetic individuals,
hyperglycemia must be controlled as early as possible, otherwise diabetes-associated endothelial dysfunction could aggravate
the damage of ischemic stroke. It is essential to preserve eNOS/endothelial function that can improve clinical outcomeswhen
diabetic individuals develop acute ischemic stroke.Diabetes mellitus has been shown to aggravate brain
injury induced by ischemic stroke and is associated with
higher mortality, worse functional outcome, and increased
frequency for recurrent stroke.1,2 The mechanism respon-
sible for the aggravating effects of diabetes on ischemic
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patients have failed to show a reduction inCVDwith intensive
glycemic control (IGC),8,9 suggesting that the pathophysi-
ology of the link between diabetes and CVD is complex,
involving more than just hyperglycemia. Currently, whether
IGC reduces risk or improves the outcome of stroke in
diabetic individuals is controversial.10-13
In addition to its hypoglycemic effect, insulin exerts
neuroprotection in diabetic rats subjected to cerebral
ischemia.14,15 However, it also has been demonstrated
that insulin attenuates brain damage independent of its
hypoglycemic effect,16 even though insulin may have
a negative impact on the central nervous system (CNS)
either directly17 or indirectly through the reduction of
circulating glucose levels.18,19 In the past, the direct effects
of insulin on the CNS have largely been ignored, since
insulin was considered incapable of crossing the blood
brain barrier.20 However, in recent years both insulin and
its receptor have been identiﬁed in the CNS and their asso-
ciated biological functions have been extensively studied.21
Glucose uptake is known to be a function of CNS activity
and insulin has been shown to increase glucose uptake in
the brain.22 Although recent studies have reported the
downregulation of cerebral glucose transporters (GLUTs)
by ischemic injury and tissue necrosis,23 the effects of dia-
betes and insulin treatment on glucose transport and
GLUT expression in the cerebral tissue with ischemic
injury remain unclear. It is generally accepted that insulin,
on binding to its receptor, initiates the tyrosine phosphor-
ylation of cellular substrates including the insulin receptor
substrate family members, which in turn modulate the acti-
vation of phosphatidylinositol 3-kinase and downstream
kinase such as Akt that are responsible for initiating
a number of cellular effects.24 These include the improve-
ment of synaptic plasticity and neuronal survival following
cerebral ischemia-reperfusion injury.24-26 Additionally,
insulin also elicits vasodilatation in vivo, a response that
can be associated with the reduced sympathetic nerve
activity, activation of ATP-dependent Kþ channels,27
release of vasodilator adenosine,28 or activation of endothe-
lial Akt for NO production.29-31 However, the effects of
insulin that result in protection against cerebral ischemic
insult in diabetes remain undeﬁned. In addition, the incon-
sistent results from use of IGC to protect cerebral function
warrant further investigation. Herein, the streptozotocin
(STZ)-induced diabetic rat model was employed to explore
the possible mechanisms contributing to the neuroprotec-
tive effect of glycemic control with insulin in focal cerebral
ischemia-reperfusion (FC I/R) injury.
METHODS
This study abides by the rules in the Guide for the Care
and Use of Laboratory Animals published by the U.S.
National Institutes of Health (NIH publication No. 85-
23, revised 1996). Six-week-old Long-Evans male rats
(National Lab. Animal Breeding and Research Center,
Taiwan) weighing 250-280 g were used throughout this
study and were maintained in the Animal Center of theChang Gung University, at an ambient temperature of
25 6 1C and a light-dark period of 12 hours. The animals
were fed with normal chow and water. All surgical proce-
dures and postoperative animal care were reviewed and
approved by the Institutional Animal Care and Use
Committee of Chang Gung University.
Induction of STZ-diabetic animal model. Rats were
fasted for 72 hours and anesthetized by intraperitoneal
injection (i.p.) of pentobarbital at a dose of 65 mg/kg.
The animals were randomly divided into two groups:
(1) age-matched nondiabetic control (CONT) and (2)
STZ-induced diabetes. The animals were subjected to
a single intravenous injection of vehicle (normal saline) for
CONT or freshly prepared STZ (65 mg/kg) for diabetes
induction. STZ has been shown to destroy pancreatic
b cells and induce hyperglycemia during the ﬁrst 24 hours
after injection.32 Two weeks later, blood glucose levels
were measured using the glucose oxidase method (Chem-
Well 2910 Automated EIA and Chemistry Analyzer
Spectra; GMI Inc, Ramsey, Minn) as described previ-
ously.33 The daily food intake was measured by weighing
the amount of food left in the container after 24 hours and
subtracting it from the initial amount of food at the start of
the day’s feeding. The daily water intake was obtained by
subtracting the volume of water remaining at the end of
24 hours of feeding from the initial amount in the water
bottle at the start of the day. The daily urine amount was
obtained from the total volume in the urine bottle after
24 hours. The daily food and water intake and urine
amount in STZ-induced diabetic rats treated with saline
vehicle (DM) rats were compared with age-matched
nondiabetic control. Animals with blood glucose levels
above 300 mg/dL and symptoms of polyphagia, polyuria,
and polydipsia were used for this study. The STZ-diabetic
animals were further randomly divided into two groups:
(1) DM and (2) diabetic rats treated with insulin (DMI).
The insulin Monotard HM (4 IU/rat/d; Novo Nordisk,
Bagsvaerd, Denmark) was administered subcutaneously to
STZ-diabetic rats for 1 week. The duration of insulin
injection was from the 15th day to the 21st day after STZ
injection. Rats were sacriﬁced on the 21st day post-
intravenous injection for all three groups.
FC I/R and infarct volume analysis. After 24 hours
of the last vehicle or insulin treatment, the rats were anes-
thetized with chlorohydrate (450 mg/kg, i.p.) and body
temperature was maintained at 37 6 0.5C with a heating
pad servo-controlled by a rectal probe. Focal ischemic
infarcts in the right lateral cerebral cortex were produced
by ligating the right middle cerebral artery (MCA) and
occluding both common carotid arteries as described in
our previous studies.34,35 Blood ﬂow in the common
carotid arteries was restored after 1 hour of occlusion,
but the right MCA ligature was left in place permanently.
Our previous studies have shown a consistent formation
of cerebral infarct in the right MCA territory following
1-hour FC I/R.34,35 Twenty-four hours after FC I/R
injury, the animals were anesthetized with urethane
(1.2 g/kg, i.p.) and killed by rapid decapitation. Brains
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Fig 1. Body weight and plasma levels of glucose and insulin.
Increased plasma glucose (A) and decreased plasma insulin level
(B) and body weight (C) resulting from streptozotocin (STZ)
injection were reversed by insulin treatment. Values are expressed
as mean 6 standard error of the mean. CONT, Age-matched
nondiabetic controls (n ¼ 28); DM, STZ-induced diabetic rats
(n ¼ 29); DMI, insulin-treated diabetic rats (n ¼ 28); FC I/R,
focal cerebral ischemia-reperfusion.
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of hemorrhage or infection were accepted for further
study. Brains were immersed in cold saline solution for
10 minutes and sectioned into standard coronal slices
(each 2-mm thick) using a brain matrix slicer (Jacobowitz
Systems; Zivic-Miller Laboratories Inc, Allison Park,
Pa). Slices were placed in the vital dye 2, 3, 5-
triphenyltetrazolium chloride (TTC, 2%; Sigma, St.
Louis, Mo) at 37C and kept in the dark for 30 minutes,
followed by 10% formalin treatment at room temperature
overnight. The outline of the right and left cerebral
hemispheres as well as that of the infarcted tissue, which
lacks TTC staining,1 was visualized on the posterior
surface of each slice using an image analyzer (color image
scanner, EPSON GT-9000; Epson America Inc, Long
Beach, Calif) coupled to an image analysis system (AIS
Software; Imaging Research Inc, St. Catharines, Ontario,
Canada). Infarct volume was calculated as the sum of
infarct area per slice multiplied by slice thickness. Both
the surgeon and image analyzer operator were blinded to
the treatment of each animal.
Assessment of neurologic functions. Twenty-four
hours after FC I/R injury, the modiﬁed Bederson score36
was used to determine global neurologic function accord-
ing to the following scoring system: 0, no deﬁcit; 1, forelimb
ﬂexion; 2, decreased resistance to lateral push; 3, unidirec-
tional circling; 4, longitudinal spinning; and 5, no move-
ment. Motor function and coordination were evaluated by
the grip test.37 For grip testing, the rat was placedmidway on
a string between two supports and rated as follows: 0, falls
off; 1, hangs onto string by one or both forepaws; 2, as for 1,
and attempts to climb onto string; 3, hangs onto string by
one or both forepaws plus one or both hind-paws; 4, hangs
onto string by fore- and hind-paws plus tail wrapped around
string; and 5, escape (to the supports). Neurologic scores
were assessed by an independent and blinded investigator.
Assessment of cerebral glucose uptake. To compare
cerebral glucose uptake in control, DM, and insulin-treated
DM rats, 2-deoxy-[3H] glucose (2-DG; PerkinElmer,
Boston, Mass) was administered as an intravenous bolus
(1.85 MBq) at the end of FC I/R injury. Brain tissue from
the right cerebrum with MCA occlusion (ipsilateral) was
harvested for 2-DG uptake and protein analysis. The left
cerebrum (contralateral) was used as non-I/R control from
the same animal. The method for measurement of cerebral
glucose uptake has been described in our previous
studies.33 Brieﬂy, blood samples (0.05 mL) from the
femoral artery were collected for glucose and 2-DG
measurement at 5, 10, 20, 40, and 80 minutes after
intravenous injection of 2-DG (1.85 MBq). Brain tissues
were also collected at the last blood sample collection
80 minutes after intravenous injection of 2-DG. Because
2-DG is a glucose analog that is phosphorylated but not
further metabolized in the tissue, glucose uptake in cere-
bral tissues can be estimated by determining the tissue
content of 2-DG-6-P and the plasma 2-DG proﬁle, then
ﬁtting to a double exponential or linear curve. The
concentration of phosphorylated 2-DG in tissues wascalculated as the difference between total 3H-radioactivity
of the tissue extracts and the 3H-radioactivity remaining
after Somogyi treatment.33,38
Protein extraction and Western blot analysis. The
membranous and cytoplasmic fraction of cerebral tissue
were isolated as described in our previous studies.33,35
Protein (30 mg) from cytoplasmic and membranous
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Fig 2. Focal cerebral ischemia-reperfusion (FC I/R)-induced brain infarction and neurologic deﬁcits. FC I/R-induced
brain infarction (A and B) and neurologic deﬁcits (C and D) exacerbated by diabetes were rescued by insulin treat-
ment. A, Shows representative coronal sections and (B) shows mean 6 standard error of the mean of quantitative
infarct volume. Neurologic functions were assessed by Bederson score (C) and grip test (D) in age-matched nondi-
abetic controls (CONT, n ¼ 19), STZ-induced diabetic rats (DM, n ¼ 21), and insulin-treated diabetic rats
(DMI, n ¼ 12). Values are expressed as mean 6 standard error of the mean.
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polyacrylamide gel electrophoresis and electrophoretically
transferred to polyvinylidene diﬂuoride protein-
sequencing membrane for 2 hours. The membrane was
blocked with 5% nonfat milk in Tris-buffered saline with
0.1% Tween-20. It was then washed and blotted with
antibodies against glucose transporter isoforms GLUT1
(Chemicon, Billerica, Mass), GLUT3 (Chemicon) and
GLUT8 (Santa Cruz Biotechnology, Dallas, Tex). The
membrane was then incubated with horseradish peroxidase-
conjugated secondary antibody prior to chemiluminescence
detection (Pierce, Rockford, Ill). The expression of nitric
oxide synthase (NOS) isoforms neuronal NOS (nNOS;
Upstate, Billerica, Mass), inducible NOS (iNOS; Chem-
icon), endothelial NOS (eNOS; Chemicon) and phospho-
eNOS (ser1177; Cell Signaling, Danvers, Mass), as well
as Akt (Santa Cruz Biotechnology) and phospho-Akt
(ser473; Cell Signaling), was also analyzed. Tubulin and
Naþ-Kþ ATPase were used as internal loading control for
the cytosolic and membranous fractions, respectively.
Biochemical analysis. Blood was collected from the
tail vein for biochemical measurements in experimental
rats. Plasma was used for the measurements of glucose andinsulin. Insulin was measured using a commercial available
kit provided by Mercodia (rat insulin enzyme-linked immu-
nosorbent assay kit; Mercodia, Uppsala, Sweden). Blood
glucose levels were determined by the glucose oxidase
method (ChemWell 2910 Automated EIA and Chemistry
Analyzer Spectra, GMI Inc).
Statistical analysis. Data are expressed as mean 6
standard error of mean. Statistical analysis of differences
were carried out by one-way analysis of variance
(ANOVA) for combined data and followed by Bonferroni
test. P < .05 was considered to be statistically signiﬁcant.
RESULTS
Body weight and plasma levels of glucose and
insulin. Animals treated with STZ consistently devel-
oped hyperglycemia and hypoinsulinemia that persisted
throughout a 3-week period of study. Plasma glucose and
insulin levels in diabetic rats were 457 6 24 mg/dL and
1.1 6 0.2 mg/L compared with 117 6 6 mg/dL and
2.7 6 0.2 mg/L in age-matched nondiabetic controls,
respectively (Fig 1, A and B). As expected, diabetic rats had
lower body weights compared with the age-matched
controls (306 6 4 vs 387 6 3 g; Fig 1, C). In contrast,
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Fig 3. Cerebral glucose uptake and glucose transporter (GLUT) protein expression. Cerebral tissues from ischemia-
reperfusion (I/R) side (Ipsilateral) and the non-I/R counterpart (Contralateral) were harvested from controls
(CONT, n ¼ 7), diabetic (DM, n ¼ 9), and insulin-treated diabetic (DMI, n ¼ 6) rats for biochemical analyses.
Diabetes and focal cerebral (FC) I/R injury-impaired cerebral glucose uptake (A) and GLUT1 translocation to the
plasma membrane (B and C), which were not affected by insulin treatment. Both GLUT3 and GLUT8 were not
altered by experimental interventions (B). All experiments were performed in triplicates from at least four animals.
Values are expressed as mean 6 standard error of the mean.
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attenuated STZ-induced hyperglycemia (128 6 11 vs
457 6 24 mg/dL), hypoinsulinemia (3.3 6 0.3 vs 1.1 6
0.2 mg/L), and weight loss (330 6 4 vs 306 6 4 g)
(Fig 1). The elevation in plasma glucose and reduction in
plasma insulin were signiﬁcantly different between DM and
control groups but not signiﬁcantly different between the
insulin-treated and the control group.
FC I/R-induced brain infarction and neurologic
deﬁcits. There were no statistical differences in blood gas
parameters (PO2, PCO2, and pH) of the animals among
groups (data not shown) and FC I/R (n ¼ 19)-generated
cerebral infarcts with an average volume of 219.7 6
24.8 mm3 in volume (Fig 2). The infarct size was signiﬁ-
cantly increased by about 60% in STZ-diabetic rats (P <
.001, n ¼ 21; Fig 2, A and B). In addition to its hypo-
glycemic effect, insulin treatment signiﬁcantly reduced
FCI/R-induced infarct volume from 346.9 6 19.8 to
273.7 6 17.8 mm3 (P < .05, n ¼ 12; Fig 2, A and B). For
evaluation of neurologic functions, the Bederson and grip
tests were performed to examine postural reﬂexes and
muscle strength, respectively. After ischemic stroke, the
Bederson and grip scores were 1.6 6 0.2 and 3.5 6 0.4 in
nondiabetic control rats, respectively (Fig 2, C and D).
Both postural reﬂex and muscle strength were further
impaired in diabetic animals (Fig 2, C and D). The adverseeffects of diabetes on neurologic function were prevented
in animals treated with insulin (Fig 2, C and D).
Cerebral glucose uptake and GLUT protein
expression. The effect of FC I/R injury on cerebral
glucose uptake and GLUT protein expression were exam-
ined in control and diabetic animals with or without insulin
treatment. The glucose uptake in ipsilateral cerebrum sub-
jected to I/R was reduced by about 29% compared with its
contralateral control without I/R (Fig 3, A). Diabetes
alone also compromised the glucose uptake rate by 38%,
but FC I/R injury did not further reduce glucose uptake
activity in diabetic animals (Fig 3, A). Insulin treatment
failed to improve cerebral glucose uptake in diabetic rats
with or without FC I/R injury (Fig 3, A).
Expression of GLUT proteins (GLUT 1, 3, and 8) in
contralateral and ipsilateral brain tissue was examined by
Western blotting. For membranous proteins, the
GLUT1 expression was signiﬁcantly reduced by diabetes
in contralateral non-I/R tissue (Fig 3, B and C). Insulin
treatment has a tendency, but not in a signiﬁcant manner,
to improve GLUT1 expression (Fig 3, B and C). FC I/R
injury on the ipsilateral tissue signiﬁcantly reduced
GLUT1 expression, and diabetes did not further reduce
the expression. Insulin treatment had no effect on the sup-
pressed GLUT1 expression (by FC I/R injury) in diabetic
animals (Fig 3, B and C). For cytosolic proteins, GLUT1
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Fig 4. Cerebral Akt and endothelial nitric oxide synthase (eNOS) phosphorylation. Cerebral tissues from ischemia-
reperfusion (I/R) side (Ipsilateral) and the non-I/R counterpart (Contralateral) were harvested from controls
(CONT), diabetic (DM), and insulin-treated diabetic (DMI) rats for protein analyses. The reduced cerebral eNOS
(A and B) and Akt (C and D) phosphorylation in diabetes with or without focal cerebral ischemia-reperfusion
(FC I/R) injury was corrected by insulin treatment. All experiments were performed in triplicates from at least
four animals. Values are expressed as mean 6 standard error of the mean. p-eNOS, Phosphorylated eNOS;
iNOS, inducible NOS; nNOS, neuronal NOS.
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in diabetic animals with or without insulin treatment
(Fig 3, B and C). FC I/R injury also had no effect on
the cytosolic GLUT1 expression, but this insult signiﬁ-
cantly reduced GLUT1 expression in the diabetic animals
in a manner insensitive to insulin treatment (Fig 3, B
and C). In contrast, the GLUT3 and GLUT8 protein
expressions were not signiﬁcantly different among the
groups (Fig 3, B).
Cerebral Akt and eNOS phosphorylation. In
parallel with the glucose transporter expression studies,
cerebral Akt and eNOS protein expression and phosphory-
lation levels were examined. The expression of NOS
protein isoforms (ie, eNOS, iNOS, and nNOS) was not
altered by either FC I/R injury or diabetes (Fig 4, A).
However, the phosphorylated eNOS (p-eNOS) protein
levels were 100, 67 6 5, and 120 6 22% in the contra-
lateral tissues of control, DM, and DMI groups, respec-
tively (Fig 4, A and B). The level p-eNOS protein was
reduced by diabetes in an insulin-sensitive manner (Fig 4,
B). The p-eNOS protein levels were 119 6 20, 51 6 10,
and 91 6 13% in the ipsilateral tissues of control, DM, and
DMI groups, respectively (Fig 4, A and B). FC I/R injury
slightly increased p-eNOS expression in nondiabetic
animals, but this insult caused a marked reduction ofp-eNOS expression in diabetic animals that was prevented
by treating the animals with insulin (Fig 4, A and B).
The expression of total Akt protein was not altered by
either FC I/R injury or diabetes (Fig 4, C). Although the
level of phosphorylated Akt (p-Akt) in non-I/R contralat-
eral tissue was not altered by diabetes, it was increased by
more than threefold in diabetic animals treated with insulin
(Fig 4, C and D). FC I/R injury in ipsilateral tissue caused
a signiﬁcant increase in p-Akt expression, which was not
observed in diabetic animals. Similar to the effect of insulin
on contralateral cerebral tissue, the p-Akt expression level
was signiﬁcantly elevated in insulin-treated diabetic rats
subjected to FC I/R insult (Fig 4, C and D).
Effect of eNOS inhibition on infarct size and
neurologic function. To elucidate the role of eNOS
and its relation to insulin in FC I/R injury in diabetes,
we examined the effects of the eNOS inhibitor, N-
iminoethyl-L-ornithine (L-NIO), on FC I/R-induced
infarct volume and neurologic deﬁcits in diabetic rats
treated with insulin. Administration of L-NIO 24 hours
prior to FC I/R in insulin-treated diabetic rats signiﬁcantly
increased infarct size (406.9 6 58.2 vs 273.7 6 17.8 mm3,
Fig 5, A and B) and reduced the neuroprotective effect of
insulin, with a resultant increase in the Bederson score
(3.3 6 0.3 vs 1.7 6 0.2; Fig 5, C) and a reduction in grip
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Fig 5. Effect of endothelial nitric oxide synthase (eNOS) inhibition on infarct size and neurologic function. A, Shows
representative coronal sections, and (B) shows quantitative infarct volume. The neurologic functions were assessed
by Bederson score (C) and grip test (D) in insulin-treated diabetic rats (DMI, n ¼ 10) and DMI cotreated with N-imi-
noethyl-L-ornithine (L-NIO) (DMI þ L-NIO, n ¼ 5) 24 hours prior to focal cerebral ischemia-reperfusion (FC I/R)
injury. Insulin-mediated prevention of FC I/R-induced brain infarction and neurologic deﬁcits in diabetes was antago-
nized by administration of the eNOS inhibitor L-NIO. Values are expressed as mean6 standard error of the mean.
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plasma level of glucose (326 6 60 vs 361 6 37 mg/dL)
and insulin (1.6 6 0.3 vs 1.6 6 0.3 mg/L) and the body
weight (321 6 13 vs 330 6 4 g) in insulin-treated diabetic
rats were not affected by L-NIO (Fig 6).
DISCUSSION
The main ﬁndings of the present study are as follows.
(1) Diabetes impaired glucose uptake and membrane traf-
ﬁcking activity of GLUT1 in the cerebrum and this adverse
effect was neither aggravated by FC I/R injury nor
reversed by insulin treatment. (2) Hyperglycemia exacer-
bated FC I/R-induced stroke size and neurologic dysfunc-
tion. (3) The FC I/R-induced Akt and eNOS
phosphorylations were blunted in animals with diabetes.
(4) In parallel with its hypoglycemic effects, insulin also
increased cerebral Akt/eNOS phosphorylations and
improved neurologic function in diabetes. (5) Inhibition
of eNOS abrogated the insulin-induced neuroprotective
effects of reduced cerebral infarct volume and neurologic
deﬁcits in diabetic rats without affecting insulin-induced
hypoglycemia, hyperinsulinemia, and weight recovery.
The brain uses glucose as its primary substrate for
energy production. Delivery of glucose from the blood to
the brain requires transport across the endothelial cells of
the blood-brain barrier and into the neurons and glia cells.
Facilitative glucose transporter proteins mediate these
processes. The three primary glucose transporter isoformsthat function in cerebral glucose metabolism are GLUT1,
GLUT3 and GLUT8.39,40 In the present study, we
showed that cerebral glucose uptake and membrane traf-
ﬁcking activity of GLUT1 were compromised in STZ-
diabetic rats. The ultimate consequence of these reductions
may make the diabetic animal susceptible to FC I/R injury
and worsen the neurologic outcomes. However, the
impairment of glucose uptake and GLUT1 membrane traf-
ﬁcking activity seen with diabetes were not exacerbated by
FC I/R, suggesting there is no causal relationship between
those two events. On the other hand, insulin treatment
signiﬁcantly ameliorated hyperglycemia, hypoinsulinemia,
infarct volume, and neurologic deﬁcits but did not improve
membranous GLUT 1 protein level and glucose uptake. It
appears that the beneﬁcial action of insulin upon FC I/R
injury is independent of cerebral glucose uptake.
Recently, endothelial dysfunction has been demon-
strated to be one of the earliest detectable events in
diabetes-associated ischemic stroke.41 Impairment of
eNOS-dependent vascular function may contribute to
a reduction of cerebral blood ﬂow in stroke.42,43 A previous
study also showed that abnormalities in eNOS phosphoryla-
tion are an important common pathway that links diverse
cardiovascular risks (such as diabetes, obesity, andmetabolic
syndrome) with endothelial dysfunction to increase the
propensity to ischemic stroke.44 In addition, insulin can acti-
vate eNOS through Akt-mediated S1179 phosphorylation,
thereby increasing blood ﬂow and cell survival.45,46 In the
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Fig 6. Effect of N-iminoethyl-L-ornithine (L-NIO) on body
weight and plasma levels of insulin and glucose. The plasma levels
of glucose (A) and insulin (B) and the body weight (C) in diabetic
rats were not affected by administration of the endothelial nitric
oxide synthase (eNOS) inhibitor L-NIO. Values are expressed as
mean 6 standard error of the mean. DMI, Insulin-treated diabetic
rats (n ¼ 10); DMI þ L-NIO, DMI cotreated with L-NIO
24 hours prior to focal cerebral ischemia-reperfusion (FC I/R)
injury (n ¼ 5).
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eNOS and Akt in the cerebral tissue was increased after
FC I/R injury. This may exert compensatory protection
mechanisms against neurologic injury by I/R. This context
is supported by the ﬁnding that diabetes attenuated the
increased cerebral eNOS/Akt phosphorylation in parallelwith a worse neurologic outcome in FC I/R injury. Inter-
estingly, insulin enhanced the cerebral Akt and eNOS
phosphorylation levels and also alleviated FC I/R injury in
STZ-diabetic rats. To examine whether eNOS was respon-
sible for the neuroprotective effect of insulin in diabetes
with FC I/R injury, we administered a selective eNOS
inhibitor L-NIO to the STZ-diabetic rats. In agreement
with the eNOS/Akt phosphorylation data, inhibition of
eNOS signiﬁcantly antagonized neuroprotective effects of
insulin in FC I/R-injured diabetic animals without affecting
the antihyperglycemic effect of insulin. Our results suggest
that normal vascular endothelial function is essential for
insulin protection against FC I/R injury in diabetic rats.
Consistent with our ﬁndings, Fanne et al reported that
insulin and glucagon exert neuroprotective effects that
correlate with their capacity to reduce glutamate, rather
than by modifying glucose levels.46
CONCLUSIONS
In summary, glycemic control with insulin treatment
may have clinical beneﬁts for stroke patients with diabetes,
especially in those with insulinopenic diabetes. Our results
point to a role for Akt/eNOS signaling in the detrimental
and protective effects of diabetes and insulin, respectively,
in the context of ischemic stroke. Our ﬁndings indicate
that the impact of insulin in diabetes with acute ischemic
stroke is concurrently dependent on both eNOS signaling
and antihyperglycemic effects.2,47 When eNOS dysfunction
(eg, vascular endothelial dysfunction) is developed in
patients with diabetes, the beneﬁcial effect of insulin might
be diminished in acute ischemic stroke in spite of its
preserved antihyperglycemic effect. For diabetic individ-
uals, hyperglycemia must be controlled as early as possible,
otherwise diabetes-associated endothelial dysfunction
could aggravate the damage of ischemic stroke. It is essen-
tial to preserve eNOS/endothelial function that can
improve clinical outcomes when diabetic individuals
develop acute ischemic stroke.
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